Publication: Effects of atorvastatin on human C-reactive protein metabolism
6
item.page.dc.date.issued
2013-02-01
item.page.dc.type
item.page.dc.identifier.issn
18791484
00219150
00219150
item.page.dc.identifier.doi
item.page.dc.identifier.other
2-s2.0-84872410105
item.page.dc.rights
Mahidol University
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Atherosclerosis. Vol.226, No.2 (2013), 466-470
punsarn.item.page.citation
Nuntakorn Thongtang, Margaret R. Diffenderfer, Esther M.M. Ooi, Bela F. Asztalos, Gregory G. Dolnikowski, Stefania Lamon-Fava, Ernst J. Schaefer Effects of atorvastatin on human C-reactive protein metabolism. Atherosclerosis. Vol.226, No.2 (2013), 466-470. doi:10.1016/j.atherosclerosis.2012.11.012 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/32556
Research Projects
Organizational Units
Authors
Journal Issue
relationships.isThesisOf
item.page.dc.title
Effects of atorvastatin on human C-reactive protein metabolism
item.page.dc.contributor.author
item.page.dc.contributor.other
item.page.dc.description.abstract
Objective: Statins are known to reduce plasma C-reactive protein (CRP) concentrations. Our goal was to define the mechanisms by which CRP was reduced by maximal dose atorvastatin. Methods: Eight subjects with combined hyperlipidemia (5 men and 3 postmenopausal women) were enrolled in a randomized, placebo-controlled double-blind, cross over study. Subjects underwent a 15-h primed-constant infusion with deuterated leucine after 8 weeks of placebo and 80 mg/day of atorvastatin. CRP was isolated from lipoprotein deficient plasma, (density > 1.21 g/ml) by affinity chromatography. Isotopic enrichment was determined by gas chromatography/mass spectrometry. Kinetic parameters were determined using compartmental modeling. Paired t test and Wilcoxon signed ranks test were used to compare differences between placebo and atorvastatin. Results: Compared with placebo, atorvastatin decreased median CRP pool size by 28.4% (13.31 ± 3.78 vs 10.26 ± 3.93 mg; p = 0.16), associated with a median CRP fractional catabolic rate increase of 39.9% (0.34 ± 0.06 vs 0.50 ± 0.11 pools/day; p = 0.09), with no significant effect on median CRP production rate (0.050 ± 0.01 vs 0.049 ± 0.01 mg/kg/day; p = 0.78). Conclusion: Our data indicate that maximal doses of atorvastatin lower plasma CRP levels by substantially decreasing the median CRP plasma residence time from 2.94 days to 2.0 days, with no significant effect on the median CRP production rate. © 2012 Elsevier Ireland Ltd.
